1. 3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC). (September 2015) Authors: Calvo, E.; López-Martin, J.A.; Bendell, J.; Eder, J.P.; Taylor, M.; Ott, P.A.; Pietanza, M.C.; Horn, L.; Jäger, D.; Braud, F. De; Morse, M.A.; Ascierto, P.A.; Le, D.T.; Amin, A.; Evans, J.; Simon, J.; Lin, C.S.; Christensen, O.; Antonia, S.J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S633 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma. (September 2015) Authors: Dummer, R.; Sandhu, S.; Hassel, J.C.; Muñoz, E.; Berking, C.; Gesierich, A.; Ascierto, P.A.; Esposito, O.; Carter, K.; Antona, V.; Radhakrishnan, R.; Cui, X.; Caponigro, G.; Jaeger, S.; Demuth, T.; Miller Jr, W.H. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S667 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study. (September 2015) Authors: Hansson, J.; Bartley, K.; Grob, J.J.; Kuntsfeld, R.; Dréno, B.; Mortier, L.; Ascierto, P.A.; Licitra, L.; Dutriaux, C.; Jouary, T.; Meyer, N.; Guillot, B.; Dummer, R.; Fife, K.; Ernst, D.S.; Yim, Y.M.; Williams, S.; Fittipaldo, A.; Basset-Seguin, N.; Hauschild, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S680 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3343 Exploratory analysis of vismodegib (VISMO) treatment discontinuation in the STEVIE study. (September 2015) Authors: Hauschild, A.; Hansson, J.; Grob, J.J.; Kunstfeld, R.; Dréno, B.; Mortier, L.; Ascierto, P.A.; Dummer, R.; Licitra, L.; Fife, K.; Ernst, D.S.; Dutriaux, C.; Jouary, T.; Meyer, N.; Guillot, B.; Williams, S.; Tandon, M.; Hou, J.; Basset-Seguin, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S681 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 3346 BeyPro1: a Phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with Vemurafenib, with the association of Vemurafenib plus Fotemustine. (September 2015) Authors: Queirolo, P.; Spagnolo, F.; Picasso, V.; Simeone, E.; Grimaldi, A.M.; Curvietto, M.; Giorello, L.; Fontana, V.; Merlo, D.F.; Ascierto, P.A.; Bruzzi, P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S683 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. (1st October 2019) Authors: Quagliariello, V.; Passariello, M.; Coppola, C.; Rea, D.; Barbieri, A.; Scherillo, M.; Monti, M.G.; Iaffaioli, R.V.; De Laurentiis, M.; Ascierto, P.A.; Botti, G.; De Lorenzo, C.; Maurea, N. Journal: International journal of cardiology Issue: Volume 292(2019) Page Start: 171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. CD73 activity and outcome of advanced melanoma patients treated with nivolumab. (March 2018) Authors: Morello, S.; Sorrentino, C.; Capone, M.; Giannarelli, D.; Madonna, G.; Mallardo, D.; Grimaldi, A.M.; Pinto, A.; Ascierto, P.A. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 1 Page Start: S22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. (July 2018) Authors: Cavalieri, S.; Perrone, F.; Miceli, R.; Ascierto, P.A.; Locati, L.D.; Bergamini, C.; Granata, R.; Alfieri, S.; Resteghini, C.; Galbiati, D.; Busico, A.; Paielli, N.; Patuzzo, R.; Maurichi, A.; Gallino, G.; Ruggeri, R.; Mariani, L.; Palla, M.; Licitra, L.; Bossi, P. Journal: European journal of cancer Issue: Volume 97(2018) Page Start: 7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Electrochemotherapy in melanoma: a European e-Delphi survey to define a consensus on indications, treatment modalities and quality indicators. Issue 2 (February 2019) Authors: Campana, L.G.; Quaglino, P.; Bechara, F.G.; Marconato, R.; Ascierto, P.A.; Caracò, C.; Brizio, M.; Clover, J.; Bourke, M.; Valpione, S.; Sersa, G.; Kunte, C.; Mühlstädt, M.; Gerlini, G.; Hafner, J.; Patuzzo, R.; Farronato, S.; Orlando, A.; Eisendle, K.; Kis, E. Journal: European journal of surgical oncology Issue: Volume 45:Issue 2(2019) Page Start: e18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. EP-1392: The abscopal effect:efficacy of radiotherapy in patients on progression after ipilimumab 3 mg/kg. (April 2016) Authors: Grimaldi, A.M.; Ascierto, P.A.; Simeone, E.; Giannarelli, D.; Falivene, S.; Borzillo, V.; Giugliano, F.; Sandomenico, F.; Petrillo, A.; Curvietto, M.; Esposito, A.; Paone, M.; Palla, M.; Palmieri, G.; Caraco, C.; Ciliberto, G.; Mozzillo, N.; Muto, P. Journal: Radiotherapy and oncology Issue: Volume 119(2016)Supplement 1 Page Start: S649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗